Clinical Trial

The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

Study acronym: MARCO
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) trial is a single center prospective adaptive phase 1b clinical trial in patients who are hospitalized with complications of liver disease and have low fecal metabolite levels (butyrate and deoxycholic acid). The study intervention is 1 of 9 novel live Commensal Consortia each containing eight commensal bacterial strains derived from healthy donors. The primary objective of the study is to determine safety and tolerability of Commensal Consortia administration.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-06; most recent amendment 2025-11-03.
Status change: Not Yet Recruiting → Recruiting 2025-08-04
Trial Details
NCT Number NCT06871111
Lead Sponsor University of Chicago
Conditions Liver Diseases, Liver Failure, Cirrhosis, Liver
Enrollment 24 participants
Start Date 2025-08-04
Primary Completion 2027-08-04 (estimated)
Study Completion 2028-02-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-04